APO B / APO A1 Ratio (Apolipoprotein B to Apolipoprotein A1 Ratio): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

The APO B / APO A1 ratio is one of the most powerful predictors of atherosclerotic cardiovascular disease risk. It captures the balance between pro‑atherogenic and anti‑atherogenic lipoprotein particles.

· Apolipoprotein B (APO B) is the primary structural protein found in very low‑density lipoprotein (VLDL), intermediate‑density lipoprotein (IDL), low‑density lipoprotein (LDL), and lipoprotein(a). Each atherogenic particle carries exactly one APO B molecule. Therefore APO B directly counts the total number of atherogenic particles, not just their cholesterol content. It is superior to LDL‑C when LDL particles are small and dense (high particle number with normal cholesterol) or in hypertriglyceridaemia.

· Apolipoprotein A1 (APO A1) is the major protein of high‑density lipoprotein (HDL). It mediates reverse cholesterol transport and has anti‑inflammatory, antioxidant properties. APO A1 reflects HDL particle number, not just HDL‑cholesterol.

The APO B / APO A1 ratio integrates both drivers of plaque formation and protection. A high ratio indicates particle excess of atherogenic lipoproteins relative to protective HDL particles. This ratio predicts myocardial infarction, stroke, and peripheral arterial disease more accurately than conventional LDL‑C, HDL‑C, or total cholesterol / HDL‑C ratio in many populations.

---

2. What does it measure

a. Units of measurement

· APO B: milligrams per decilitre (mg/dL) or grams per litre (g/L)

· APO A1: milligrams per decilitre (mg/dL) or grams per litre (g/L)

· APO B / APO A1 ratio: dimensionless (calculated as APO B ÷ APO A1)

b. Normal Range and Optimal Targets

(Reference ranges vary by laboratory, age, sex, and assay method; the ratio is a continuous risk marker, not a diagnostic threshold.)

For APO B:

· Optimal (low risk): less than 80–90 mg/dL

· Moderate risk: 90–120 mg/dL

· High risk: greater than 120 mg/dL

For APO A1:

· Optimal (low risk): greater than 120–140 mg/dL (higher is better)

· Low: less than 100–120 mg/dL

For APO B / APO A1 Ratio:

· Males:

· Optimal: less than 0.65

· Moderate risk: 0.65–0.80

· High risk: greater than 0.80

· Females:

· Optimal: less than 0.55

· Moderate risk: 0.55–0.70

· High risk: greater than 0.70

Interpretation notes:

· In primary prevention, an APO B / APO A1 ratio less than 0.6 is often cited as ideal.

· Values greater than 0.7 in women and greater than 0.8 in men indicate substantially elevated cardiovascular risk.

· APO B alone at or above 130 mg/dL is considered high; at or above 160 mg/dL is very high.

· APO A1 alone less than 120 mg/dL in men or less than 130 mg/dL in women is low.

(These are general guidelines; treat according to global cardiovascular risk assessment, not isolated numbers.)

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise APO B or lower APO A1, thus raising the ratio)

Factors that increase APO B (more atherogenic particles):

· Genetic – familial hypercholesterolaemia (LDL receptor mutations), familial combined hyperlipidaemia, APOB gene mutations, polygenic hypercholesterolaemia.

· Dietary – high intake of saturated fats, trans fats, refined carbohydrates, excess fructose; these increase hepatic VLDL secretion and thus APO B production.

· Insulin resistance / type 2 diabetes – increased flux of free fatty acids to liver, upregulation of APO B‑containing particles.

· Obesity – particularly visceral adiposity.

· Hypothyroidism – reduces LDL receptor expression, raising APO B.

· Chronic kidney disease – impaired clearance of APO B lipoproteins.

· Medications – some progestins, anabolic steroids, isotretinoin, certain antipsychotics.

· Menopause – oestrogen decline leads to higher LDL particle number.

Factors that decrease APO A1 (less protective HDL particles):

· Insulin resistance, metabolic syndrome, type 2 diabetes – accelerate HDL catabolism.

· Hypertriglyceridaemia – triglyceride‑rich lipoproteins promote cholesterol ester transfer protein (CETP) activity, depleting HDL cholesterol and APO A1.

· Obesity – associated with low APO A1.

· Smoking – directly lowers APO A1.

· Physical inactivity – reduces HDL turnover.

· Genetic – rare APO A1 mutations, familial hypoalphalipoproteinaemia.

· Medications – androgens, progestins, beta‑blockers (non‑vasodilating), thiazide diuretics may lower HDL‑C but effect on APO A1 is variable.

b. Indirect correlation (factors that influence the ratio independently or through assay issues)

· Age – APO B tends to increase until middle age, then plateau; APO A1 declines slightly with age. Ratio rises.

· Sex – premenopausal women have higher APO A1 and lower APO B; ratio is naturally lower. After menopause, ratio increases toward male pattern.

· Pregnancy – APO B rises, APO A1 also rises but ratio may increase; cardiovascular risk assessment during pregnancy not standard.

· Ethnicity – South Asians often have higher APO B and lower APO A1 for same LDL‑C, leading to higher ratio and increased risk.

· Alcohol – moderate intake raises APO A1 (HDL), but not recommended as intervention; excess alcohol raises triglycerides and APO B.

· Acute inflammation / infection – APO A1 falls as a negative acute phase reactant; APO B may be variably affected. Ratio transiently elevated; not interpretable during acute illness.

· Medications –

· Statins lower APO B (modestly), may slightly raise APO A1 → ratio improves.

· Fibrates lower APO B (modestly), raise APO A1 → ratio improves.

· Niacin raises APO A1 (but side effects limit use; synthetic immediate‑release form often poorly tolerated; extended‑release may be used; ecological sourcing not relevant).

· CETP inhibitors raise APO A1 substantially but cardiovascular outcome trials were mixed; not routinely used.

· Oestrogen raises APO A1, lowers APO B.

· Fasting status – APO B and APO A1 are minimally affected by recent meals; non‑fasting samples are acceptable for ratio measurement, unlike LDL‑C.

---

4. Disorders related to abnormal values

a. When the ratio is elevated (pro‑atherogenic state)

· Atherosclerotic cardiovascular disease – coronary artery disease, myocardial infarction, stroke, peripheral artery disease. The ratio is a continuous, graded risk marker.

· Familial combined hyperlipidaemia – elevated APO B, normal or elevated LDL‑C, elevated triglycerides.

· Familial hypercholesterolaemia – markedly elevated LDL‑C and APO B.

· Metabolic syndrome / insulin resistance / type 2 diabetes – high APO B (often with normal LDL‑C due to small dense LDL), low APO A1.

· Chronic kidney disease – particularly stage 3–5, nephrotic syndrome.

· Hypothyroidism – untreated.

· Obstructive liver disease – abnormal lipoprotein X may interfere, but APO B often elevated.

· HIV infection / antiretroviral therapy – some protease inhibitors increase APO B.

· Polycystic ovary syndrome – due to insulin resistance.

b. When the ratio is low (potentially protective, but can be pathologically low)

· Low ratio is generally desirable (high APO A1, low APO B).

· Pathologically low APO B (hypobetalipoproteinaemia) – rare genetic conditions (abetalipoproteinaemia, familial hypobetalipoproteinaemia); may cause fat malabsorption, neurological deficits, but cardiovascular risk is very low.

· Pathologically high APO A1 – rare; some genetic variants; no clinical syndrome.

· Severe hyperthyroidism – can lower APO B.

· Malnutrition / advanced liver disease – reduced synthesis of all apolipoproteins.

---

5. Best way to address aberrant levels

Important principle: The APO B / APO A1 ratio is a risk marker, not a disease. Lowering an elevated ratio means reducing atherogenic particle numbers and/or increasing protective HDL particle numbers. This is achieved through lifestyle modifications that address insulin sensitivity, dietary fat quality, and, when indicated, pharmacotherapy. Interventions must be sustained and are typically long‑term. All decisions should be made with a healthcare professional within a global cardiovascular risk framework.

a. Quick ways or using Medications

· Statins – first‑line for lowering APO B (by upregulating LDL receptors). Effect on APO A1 is neutral or mildly positive. Atorvastatin, rosuvastatin most potent.

· Ezetimibe – reduces APO B modestly; added to statin for incremental lowering.

· PCSK9 inhibitors – evolocumab, alirocumab; dramatically lower APO B (50–60%) and also lower lipoprotein(a). Reserved for very high risk or statin intolerance. (Produced via recombinant DNA technology; ecologically acceptable as biotechnology products.)

· Fibrates – fenofibrate, bezafibrate; lower APO B modestly, raise APO A1 (10–20%). Particularly useful when hypertriglyceridaemia predominates.

· Bempedoic acid – oral, lowers APO B (approximately 15–20%); alternative for statin‑intolerant patients.

· Icosapent ethyl – purified ethyl ester of eicosapentaenoic acid (EPA); reduces triglyceride and APO B, possibly APO A1 neutral. Derived from fish oil – not preferred due to ecological strain. Seek algal EPA sources if available; currently most prescription icosapent ethyl is fish‑derived. Consider lifestyle and other agents first.

· Niacin (nicotinic acid) – raises APO A1 (HDL) effectively but side effects (flushing, hyperglycaemia) limit use; no longer routinely recommended due to lack of outcome benefit added to statin.

· Do not self‑prescribe lipid‑lowering drugs; all require medical supervision and baseline liver/kidney function tests.

b. Using Supplements or Holistic medicine

For lowering APO B / improving ratio:

· Plant sterols and stanols – 2 g/day reduces LDL‑C and APO B by 5–15%.

· Preferred source: Derived from vegetable oils (soy, pine tree oil). Available as supplements or fortified foods.

· Form: Stanol esters in margarine spreads, capsules.

· Caution: May reduce absorption of fat‑soluble vitamins; space intake from main meals.

· Soluble fibre – psyllium, beta‑glucans (oats, barley), glucomannan, pectin.

· 5–10 g/day reduces APO B by 5–10%.

· Acts by bile acid binding, increased hepatic LDL receptor expression.

· Berberine – upregulates LDL receptor mRNA independent of statin pathway; lowers APO B, triglycerides.

· Dose: 500 mg twice daily.

· Preferred source: Standardised berberine (≥97%) from Berberis aristata or Phellodendron amurense.

· Avoid products with added synthetic folic acid or cyanocobalamin.

· Caution: GI side effects; interacts with many medications (cyclosporine, anticoagulants); not for pregnancy.

· Omega‑3 fatty acids (EPA/DHA) – modest triglyceride lowering, may reduce APO B in hypertriglyceridaemic individuals.

· Preferred source: Algae oil – sustainable, plant‑based, direct EPA/DHA. Avoid conventional fish oil (overfishing, ocean pollutants).

· Dose: 2–4 g/day EPA/DHA for triglyceride effect; lesser doses for general health.

· Form: re‑esterified triglyceride form for optimal absorption.

· Monacolin K (red yeast rice) – contains naturally occurring lovastatin; lowers APO B.

· Caution: Potency varies; risk of same adverse effects as statins (myopathy, hepatotoxicity). Contamination with citrinin (nephrotoxin) possible; choose certified purified products.

· Not recommended without physician oversight; regulatory status varies by country.

· Policosanol – earlier evidence not confirmed; not recommended.

For raising APO A1 (HDL particle number):

· No supplement robustly raises APO A1 to a degree that meaningfully reduces cardiovascular events.

· Niacin – effective but poorly tolerated; not recommended as supplement without medical supervision.

· Curcumin – modest evidence for increasing APO A1 in some studies; use phytosomal or liposomal curcumin for bioavailability.

· Cocoa flavanols – may increase HDL‑C, effect on APO A1 unclear; dark chocolate (>70%) in moderation.

General anti‑inflammatory / insulin sensitising supplements that indirectly improve ratio:

· Magnesium – as glycinate, citrate. Deficiency worsens insulin resistance.

· Vitamin D – D3 from lichen; deficiency linked to dyslipidaemia.

· Green tea extract (EGCG) – may lower LDL‑C and APO B; moderate effect.

Ayurvedic approaches:

· Guggulu (Commiphora mukul) – gum resin; standardised guggulsterones used for hyperlipidaemia. Efficacy modest; some products withdrawn due to hepatotoxicity concerns. Use only standardised extracts from reputable manufacturers.

· Arjuna (Terminalia arjuna) – bark extract; may improve lipid profile.

· Garlic (Allium sativum) – aged garlic extract; small LDL‑C reduction.

· Always consult a qualified practitioner; herbs can interact with statins and anticoagulants.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

Diet is the cornerstone of improving the APO B / APO A1 ratio. Both components are exquisitely sensitive to dietary patterns.

Core dietary pattern – what to emphasise:

· Whole food, plant‑based (WFPB) or Mediterranean‑style plant‑forward diet.

· Replace saturated fats with unsaturated fats –

· Use extra virgin olive oil as principal fat.

· Include nuts (walnuts, almonds), seeds (flax, chia, hemp), avocado.

· Increase soluble fibre –

· Oats, barley, psyllium, eggplant, okra, legumes (lentils, chickpeas, beans).

· Target 25–40 g fibre daily.

· Emphasise legumes – replace animal protein with lentils, beans, tofu, tempeh.

· Whole grains over refined – quinoa, brown rice, whole wheat, millets.

· Limit refined carbohydrates and added sugars – reduce hepatic VLDL/APO B secretion.

· Avoid trans fats – completely.

Specific foods with evidence for APO B lowering / ratio improvement:

· Soy protein – 25 g/day may modestly lower LDL‑C and APO B.

· Nuts – meta‑analyses show dose‑dependent LDL‑C reduction; effect on APO B proportional.

· Plant sterol‑enriched margarines – as above.

· Psyllium husk – 10 g/day with meals.

· Barley and oats – beta‑glucans.

· Green tea – catechins; 2–3 cups daily.

Foods that raise APO A1 / HDL particle number:

· Monounsaturated fats – olive oil, avocados, nuts.

· Physical activity is far more potent than any food for raising HDL/APO A1.

· Moderate alcohol raises APO A1 but is not recommended as an intervention due to net health risks.

Protein sources (hierarchy adhered):

· Plant‑based: legumes, soy products, tofu, tempeh, seitan – primary.

· Fungi / algae: mycoprotein (Quorn), spirulina, chlorella – encouraged.

· Biotechnology / lab‑grown: precision‑fermented dairy proteins (whey, casein) without animals – acceptable.

· Dairy / eggs: permitted but not emphasised; full‑fat dairy may raise LDL‑C in some individuals. Fermented dairy (yoghurt, kefir) less detrimental.

· Meat, poultry, fish: deliberately omitted. Effective plant‑based alternatives exist for all lipid‑lowering dietary patterns. There is no nutritional requirement for meat to optimise the APO B / APO A1 ratio.

What to avoid:

· Red meat, processed meats – high saturated fat and cholesterol; some evidence that gut microbiota metabolise L‑carnitine to trimethylamine N‑oxide (TMAO), a pro‑atherogenic compound. Not needed.

· Butter, cream, tropical oils (palm, coconut) in excess – high saturated fat raises APO B.

· Sugar‑sweetened beverages, ultra‑processed foods – directly increase VLDL/APO B.

---

6. How soon can one expect improvement and the ideal time frame to retest

· Diet and lifestyle changes:

· APO B reduction begins within 3–6 weeks of adopting a low‑saturated‑fat, high‑fibre diet.

· APO A1 increases more slowly and is heavily influenced by physical activity; consistent exercise for 8–12 weeks raises APO A1 measurably.

· A meaningful improvement in the ratio (e.g., 5–15%) is typically seen in 2–3 months and continues to improve over 6–12 months.

· Medications:

· Statins lower APO B within 2–4 weeks; maximal effect by 6–8 weeks.

· Fibrates raise APO A1 within 4–8 weeks.

· PCSK9 inhibitors – rapid APO B reduction (within 2 weeks).

· Ezetimibe – add‑on effect within 4 weeks.

· Supplements:

· Berberine – lipid changes detectable within 4–8 weeks.

· Plant sterols – LDL/APO B reduction within 2–4 weeks of consistent use.

· Omega‑3 (algae oil) – triglyceride and VLDL reduction in 6–12 weeks; effect on APO B modest.

Retesting interval:

· Initial therapy: repeat lipid panel including APO B and APO A1 8–12 weeks after starting or changing therapy.

· At goal: annually, or more frequently if very high risk.

· Stable lifestyle: every 1–2 years.

· Do not retest more often than every 4 weeks except in acute situations (hospitalisation, acute coronary syndrome).

---

Conclusion

The APO B / APO A1 ratio distills the lipoprotein balance into a single, powerful number. It outperforms conventional cholesterol measures because it counts the actual particles that invade the arterial wall and the particles that defend it. An elevated ratio signals an excess of atherogenic forces; correction demands a comprehensive strategy that reduces hepatic APO B secretion and, to a lesser extent, raises HDL particle number.

A plant‑based, ecologically responsible diet—rich in legumes, whole grains, nuts, olive oil, and fibre—is the most effective and sustainable way to achieve this. When pharmacological help is needed, statins and other agents are highly effective, but they work best alongside dietary excellence. Supplements such as plant sterols, berberine, and algae‑sourced omega‑3s offer modest additional benefit, provided they are in active, bioavailable forms and free from synthetic additives.

We deliberately omit animal foods from these recommendations; decades of nutritional science confirm that meat is dispensable for optimal lipoprotein health. The most heart‑protective diets on Earth are overwhelmingly plant‑based.

As with all biomarkers, the ratio is a guide, not a god. Treat the person, not the number—but when the number is high, treat it seriously, treat it early, and treat it with respect for both human bodies and planetary boundaries.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x